#Japan #Tokyo #AKT Health #DiaGen AI #Aditya Talapragada

AKT Health's Aditya Talapragada Appointed to DiaGen AI Advisory Board

In a significant development for the pharmaceutical industry, Aditya Talapragada, president of AKT Health, has been named to the Advisory Board of DiaGen AI Inc., a Vancouver-based tech bio company specializing in AI-driven tools for small molecule and peptide drug discovery. This appointment underscores the strategic alliance between two innovative companies at the forefront of life sciences and artificial intelligence.

With this partnership, both companies synergize to merge computational biology and clinical applications while expanding into international markets. DiaGen's platform is now set to leverage AKT Health's extensive network, reaching pharmaceutical partners across the Asia-Pacific, Middle East, and North America.

Talapragada's entry into the advisory board comes at a transformative time for AI in the pharmaceutical sector. The industry is rapidly transitioning from experimental AI applications to the large-scale deployment of generative AI tools within active drug development pipelines. DiaGen AI, having been recognized for its cutting-edge research at the renowned NeurIPS conference and graduating from the University of Washington's Creative Destruction Lab, is laying the groundwork for this transformation.

Aditya brings over 15 years of experience in healthcare AI, clinical development, regulatory strategy, and global life sciences markets. He has a track record of collaborating with pharmaceutical companies, biotechnology innovators, and healthcare technology firms, translating complex scientific advancements into practical clinical and commercial outcomes. His mission within AKT Health involves bridging the previously distinct fields of AI-driven molecular design and the intricate human systems involved in drug development, regulatory compliance, and market entry across borders. His career has been shaped precisely at this intersection.

His deep expertise in clinical research and regulatory strategy enables him to offer unique insights into how AI-driven tools can integrate with real-world pharmaceutical workflows to generate practical value, which supports organizations in modernizing their clinical research infrastructures and expanding data-driven healthcare capabilities across international markets.

"AI is rapidly transforming how we discover and develop therapies. What excites me most about DiaGen is the high quality of science supporting its platform and the vast potential for future expansion," Talapragada stated. He continues, "DiaGen possesses a powerful generative AI platform with the potential to redefine molecular discovery and peptide development. I look forward to contributing to its strategic growth and assisting in connecting AI-driven drug discovery with innovations in real-world clinical research, digital health data, and precision medicine. Starting first from the Pacific Rim and currently expanding to the UAE is just the beginning. The possibilities for deeper collaboration between our teams are immense, and I'm thrilled about the future we will build together."

This appointment reflects a broader industry trend towards a close-knit alliance between AI-enabled molecular drug discovery platforms and real-world clinical development ecosystems. In his advisory role with DiaGen AI, Talapragada will provide strategic guidance on navigating the development of AI-backed healthcare markets, building global partnerships, and expanding internationally, effectively connecting innovation in AI, pharmaceutical research, and digital healthcare infrastructure.

Brian D. Keen, Chairman and CEO of DiaGen AI, expressed, “We are thrilled to have Aditya join our advisory board. His unique combination of hands-on clinical development experience, leadership in healthcare AI, and truly global professional network makes him an ideal strategic advisor as DiaGen moves to its next growth stage. Aditya understands both the scientific and business facets of healthcare innovation, and his track record of building cross-border partnerships will be invaluable as we expand our platform and enter new markets, particularly in regions like the UAE where we’ve already gained traction.”

DiaGen AI and AKT Health represent a fusion of computational science innovations and global healthcare infrastructures, poised to redefine the processes of drug discovery, validation, and delivery to patients worldwide. This appointment is the first tangible sign of the future that both organizations are striving to create together.

For more details, please contact [email protected] or [email protected], or visit www.akthealth.jp and www.diagen.ai.

About AKT Health, Inc.

Founded in May 2019, AKT Health is a strategic consulting firm specializing in the healthcare and life sciences industry, headquartered in Shibuya, Tokyo, Japan. Alongside its group systems development company, Interakt, they provide advanced data management and analysis, digital transformation (DX) by integrating cutting-edge technologies like IoT, AI, big data analytics, and blockchain.

Services Offered:

• - Medical Solutions (support for HEOR, publications, and medical affairs)
• - Commercial Solutions (maximizing omni-channel, market access analysis)
• - Clinical Solutions (data management, real-world data)
• - Technical Solutions (blockchain, metaverse, AI/machine learning)

Company Profile:

• - Name: AKT Health, Inc.
• - Location: 1-16-8 Higashi, Shibuya, Tokyo
• - Representative: Aditya Talapragada Kumar
• - Established: May 2019
• - URL: https://akthealth.jp

About DiaGen AI Inc.

DiaGen AI Inc., headquartered in Vancouver, is advancing the development of diverse AI tools for small molecule and peptide drug discovery, diagnostics, and delivery. By leveraging its proprietary generative AI engine, DiaGen aims to reduce risks, speed up development, and create value in traditional drug development landscapes, thereby contributing to the advancement of precision medicine and enhancing human longevity worldwide. Their research has been selected at NeurIPS, one of the top conferences in the machine learning field, and they are a graduate of the Creative Destruction Lab at the University of Washington. For more information, visit www.diagen.ai.